Bispecific and multispecific antibodies surge as next-gen cancer therapies

Bispecific antibodies, capable of binding two distinct proteins at once, have moved from a handful of approvals in 2018 to more than twenty worldwide, driving $18 billion in revenue in 2025. Industry insiders credit this boom to improved protein production methods and the use of artificial-intelligence tools for molecule design. Researchers at the American Association for Cancer Research meeting in Boston presented multispecific antibodies that can target three or more antigens, promising greater tumor specificity, lower side-effects, and resistance mitigation.

Historically, most approved bispecifics function as T-cell engagers, physically bringing T cells into contact with cancer cells, with at least twelve such agents cleared for blood cancers. Scientists now aim to incorporate conditional activation mechanisms that keep the drugs inert until they reach the tumor site. The field’s rapid evolution reflects deeper biological understanding and engineering capability, suggesting a new wave of more precise immunotherapies on the horizon.